Metabolite ratios in 1H MR spectroscopic imaging of the prostate

Magnetic Resonance in Medicine

Volumn 73, Issue 1, 2015, Pages 1-12

  Kobus, Thiele ^a   Wright, Alan J ^a   Weiland, Elisabeth ^b   Heerschap, Arend ^a   Scheenen, Tom W J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SIEMENS AG   (Germany)

Author keywords

1H MRS; Acquisition protocols; Metabolite ratios; Prostate cancer

Indexed keywords

AMINES; BIOMOLECULES; CHROMIUM METALLOGRAPHY; DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; MERGERS AND ACQUISITIONS; UROLOGY;

1H MRS; ACQUISITION PARAMETERS; ACQUISITION PROTOCOLS; MR SPECTROSCOPIC IMAGING; MR SPECTROSCOPY; PROSTATE CANCERS; QUALITATIVE AND QUANTITATIVE APPROACHES; QUANTITATIVE APPROACH;

METABOLITES;

CHOLINE; CITRIC ACID; CREATINE; POLYAMINE; SPERMINE; TUMOR MARKER;

ARTICLE; HUMAN; MALE; METABOLITE; MODULATION; PROSTATE; PROTON NUCLEAR MAGNETIC RESONANCE; STANDARDIZATION; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; METABOLISM; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING; PROSTATIC NEOPLASMS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84919876173     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.25122     Document Type: Article

References (73)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Hoeks CMA, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261:46-66.
3. Thomas MA, Narayan P, Kurhanewicz J, Jajodia P, Weiner MW. 1H MR spectroscopy of normal and malignant human prostates in vivo. J Magn Reson B 1990;87:610-619.
4. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-466.
5. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
6. Heerschap A, Jager GJ, Van der Graaf M, Barentsz JO, Ruijs SHJ. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 1997;37:204-213.
7. Kobus T, Wright AJ, Scheenen TW, Heerschap A. Mapping of prostate cancer by 1H MRSI. NMR Biomed 2014;27:39-52.
8. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J. Quantification of cholineand ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008;60:33-40.
9. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol 2011;38:26-41.
10. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-3603.
11. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR in Biomed 2000;13:129-153.
12. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992;281:21-40.
13. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C. Stromal cells of the human prostate: initial isolation and characterization. Prostate 1998;28:89-97.
14. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006;55:1257-1264.
15. Lynch MJ, Masters J, Pryor JP, Lindon JC, Spraul M, Foxall PJ, Nicholson JK. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J Pharm Biomed 1994;12:5-19.
16. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology 1997;50:3-12.
17. Moore GJ, Sillerud LO. The pH dependence of chemical shift and spin-spin coupling for citrate. J Magn Reson B 1994;103:87-88.
18. Van der Graaf M, Heerschap A. Effect of cation binding on the proton chemical shifts and the spin-spin coupling constant of citrate. J Magn Reson B 1996;112:58-62.
19. Trabesinger AH, Meier D, Dydak U, Lamerichs R, Boesiger P. Optimizing PRESS localized citrate detection at 3 Tesla. Magn Reson Med 2005;54:51-58.
20. Mulkern RV, Bowers JL, Peled S, Williamson DS. Density-matrix calculations of the 1.5 T citrate signal acquired with volume-localized STEAM sequences. J Magn Reson B 1996;110:255-266.
21. Wilman AH, Allen PS. The response of the strongly coupled AB system of citrate to typical 1H MRS localization sequences. J Magn Reson B 1995;107:25-33.
22. Scheenen TWJ, Gambarota G, Weiland E, Klomp DWJ, Fütterer JJ, Barentsz JO, Heerschap A. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005;53:1268-1274.
23. Van der Graaf M, Jager GJ, Heerschap A. Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. Magn Reson Mater Phy 1997;5:65-69.
24. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn Reson Med 1993;29:38-43.
25. Van der Graaf M, Van den Boogert HJ, Jager GJ, Barentsz JO, Heerschap A. Human prostate: multisection proton MR spectroscopic imaging with a single spin-echo sequence-preliminary experience. Radiology 1999;213:919-925.
26. Cunningham CH, Vigneron DB, Marjanska M, Chen AP, Xu D, Hurd RE, Kurhanewicz J, Garwood M, Pauly JM. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005;53:1033-1039.
27. Verma S, Rajesh A, Fütterer JJ, Turkbey B, Scheenen TWJ, Pang Y, Choyke PL, Kurhanewicz J. Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 2010;194:1414-1426.
28. Kobus T, Wright AJ, Asten JJ, Heerschap A, Scheenen TW. In vivo 1H MR spectroscopic imaging of aggressive prostate cancer: can we detect lactate? Magn Reson Med 2014;71:26-34.
29. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson A 1996;123:226-229.
30. Males RG, Vigneron DB, Star Lack O, Falbo SC, Nelson SJ, Hricak H, Kurhanewicz J. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D H-1 magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22.
31. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321.
32. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001;46:1079-1087.
33. Cunningham CH, Vigneron DB, Chen AP, Xu D, Hurd RE, Sailasuta N, Pauly JM. Design of symmetric-sweep spectral-spatial RF pulses for spectral editing. Magn Reson Med 2004;52:147-153.
34. Gambarota G, Van der Graaf M, Klomp D, Mulkern RV, Heerschap A. Echo-time independent signal modulations using PRESS sequences: a new approach to spectral editing of strongly coupled AB spin systems. J Magn Reson 2005;177:299-306.
35. Kickler N, Gambarota G, Mekle R, Gruetter R, Mulkern R. Echo-time independent signal modulations for strongly coupled systems in triple echo localization schemes: an extension of S-PRESS editing. J Magn Reson 2010;203:108-112.
36. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate 1997;30:248-255.
37. Schipper RG, Romijn JC, Cuijpers VMJI, Verhofstad AAJ. Polyamines and prostatic cancer. Biochem Soc T 2003;31:375-380.
38. Van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magma (New York, NY 2000;10:153-159.
39. Shukla-Dave A, Hricak H, Moskowitz C, et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007;245:499-506.
40. Willker W, Flögel U, Leibfritz D. A 1H/13C inverse 2D method for the analysis of the polyamines putrescine, spermidine and spermine in cell extracts and biofluids. NMR in Biomed 1998;11:47-54.
41. Spencer NG, Eykyn TR, DeSouza NM, Payne GS. The effect of experimental conditions on the detection of spermine in cell extracts and tissues. NMR Biomed 2010;23:163-169.
42. García-Martún ML, Adrados M, Ortega MP, Fernández González I, Lõpez-Larrubia P, Viaño J, García-Segura JM. Quantitative 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn Reson Med 2011;65:329-339.
43. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, Ng WS, Cheng CW. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004;171:1482-1486.
44. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-757.
45. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009;251:122-133.
46. Lowry M, Liney GP, Turnbull LW, Manton DJ, Blackband SJ, Horsman A. Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn Reson Med 1996;36:352-358.
47. Scheenen TWJ, Fütterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol 2011;46:25-33.
48. Selnæs KM, Heerschap A, Jensen LR, Tessem MB, Schweder GJV, Goa PE, Viset T, Angelsen A, Gribbestad IS. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol 2012;47:624-633.
49. Smith S, Levante T, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object-oriented programming approach. J Magn Reson A 1994;106:75-105.
50. Naressi A, Couturier C, Devos J, Janssen M, Mangeat C, De Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141-152.
51. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43.
52. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
53. Pels P, Osturk-Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, Van Huffel S. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR in Biomed 2006;19:188-197.
54. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 2007;245:507-516.
55. Kobus T, Hambrock T, Hulsbergen-Van De Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TWJ. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol 2011;60:1074-1080.
56. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814.
57. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R. Value of magnetic resonance spectroscopy imaging and dynamic contrastenhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010;16:1875-1883.
58. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-480.
59. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debré B, Zerbib M. Negative prostatic biopsies in patients with a high risk of prostate cancer: is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005;47:582-586.
60. Lagemaat MW, Scheenen TW. Role of high-field MR in studies of localized prostate cancer. NMR Biomed 2014;27:67-79.
61. Lagemaat MW, Zechmann CM, Fütterer JJ, et al. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging 2012;35:166-173.
62. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-708.
63. Fütterer JJ, Scheenen TWJ, Heijmink SWTPJ, Huisman HJ, Hulsbergen-Van De Kaa CA, Witjes JA, Heerschap A, Barentsz JO. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42:116-122.
64. Heerschap A, De Jager G, De Koster A, Barentsz J, De la Rosette J, Debruyne F, Ruijs J. 1H MRS of prostate pathology. Proc Int Soc Magn Reson Med. Volume S1. New York, New York, USA; 1993.
65. Chen AP, Cunningham CH, Kurhanewicz J, Xu D, Hurd RE, Pauly JM, Carvajal L, Karpodinis K, Vigneron DB. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006;24:825-832.
66. Mueller Lisse UG, Vigneron DB, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional H-1 MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001;221:380-390.
67. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008;246:480-488.
68. Weis J, Ahlström H, Hlavcak P, Häggman M, Ortiz-Nieto F, Bergman A. Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy. Magn Reson Imaging 2009;27:87-93.
69. Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y, Sugimura K, Fujii M, Maruyama K, Takizawa O. Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging 2002;16:697-706.
70. van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, de la Rosette JJ, Barentsz JO, Heerschap A. Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-287.
71. Wetter A, Hübner F, Lehnert T, Fliessbach K, Vorbuchner M, Roell S, Zangos S, Luboldt W, Vogl TJ. Three-dimensional 1 H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol 2005;15:645-652.
72. Weis J, Jorulf H, Bergman A, Ortiz-Nieto F, Häggman M, Ahlström H. MR spectroscopy of the human prostate using surface coil at 3 T: metabolite ratios, age-dependent effects, and diagnostic possibilities. J Magn Reson Imaging 2011;34:1277-1284.
73. Futterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO. Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680.